RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing alternative treatments for conditions ...
Pharmaceutical Technology on MSN
RNA-targeting small molecules: a new frontier of drug discovery
With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.
University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves ...
Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) gains attention across Nasdaq index fund holdings after upgrade and strong quarterly performance.
The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...
Irish biotech Aerska raises €32M to deliver RNA medicines to the brain, targeting Alzheimer’s and Parkinson’s at their ...
Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune ...
Madrigal is eying an expansion of MASH blockbuster Rezdiffra’s capabilities via combination with precision siRNA gene ...
Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today ...
Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results